What is the fair value of Climb Bio Inc (NASDAQ-CLYM) stock?

The current fair value estimate for Climb Bio Inc (NASDAQ-CLYM) is $14.06. This implies an estimated downside of 1.1% versus the current market price.

Is Climb Bio Inc (NASDAQ-CLYM) undervalued or overvalued?

Based on the current fair value estimate, the stock is trading close to its estimated fair value.

What is the analyst price target for NASDAQ-CLYM stock?

The available analyst price target for Climb Bio Inc (NASDAQ-CLYM) is $27.57. The analyst target implies estimated upside of 94.0%.

How is the financial health of Climb Bio Inc?

The current financial health read for Climb Bio Inc (NASDAQ-CLYM) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Climb Bio Inc's next earnings date?

The next earnings date currently listed for Climb Bio Inc (NASDAQ-CLYM) is November 11, 2026.

Does Climb Bio Inc (NASDAQ-CLYM) pay dividends?

The latest available data indicates no current dividend yield for Climb Bio Inc (NASDAQ-CLYM).

What is the market capitalization of Climb Bio Inc?

The current market capitalization listed for Climb Bio Inc is 816.2 M.

What is the enterprise value of Climb Bio Inc?

The current enterprise value listed for Climb Bio Inc is 545.5 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Climb Bio Inc?

The ticker symbol for Climb Bio Inc is NASDAQ-CLYM, and the stock is listed on NASDAQ.

Where is Climb Bio Inc (NASDAQ-CLYM) listed?

Climb Bio Inc (NASDAQ-CLYM) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Climb Bio Inc?

The current debt-to-total-capital ratio listed for Climb Bio Inc is 0.2%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Climb Bio Inc?

The free float listed for Climb Bio Inc is 71.9%. Free float helps investors understand how much of the share base is available for public trading.

Climb Bio Inc (CLYM) Fair Value & Stock Analysis

Climb Bio Inc (CLYM)

Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies for patients with immune-mediated diseases. Its lead candidate, budoprutug, is an anti-CD19 monoclonal antibody being studied for B-cell mediated diseases, including primary membranous nephropathy and immune thrombocytopenia in Phase 2 trials, as well as systemic lupus erythematosus in a Phase 1b study. The company is also advancing CLYM116, a preclinical anti-APRIL monoclonal antibody being evaluated for IgA nephropathy and other B-cell mediated diseases. Formerly known as Eliem Therapeutics, Inc., the company adopted the Climb Bio name in October 2024. Climb Bio was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Dividend Yield	Next Earnings Date	Price-to-Book Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
NASDAQ-CLYM	$14.06	-1.1% Downside	Fair	$27.57	94.0% Upside	Bargain	Fair	0.0%	November 11, 2026	3.3x	816.2 M	545.5 M	0.2%	71.9%	67.9	92.1%